Cargando…

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency

TransCon growth hormone is a sustained-release human growth hormone prodrug under development in which unmodified growth hormone is transiently linked to a carrier molecule. It is intended as an alternative to daily growth hormone in the treatment of growth hormone deficiency. This was a multi-cente...

Descripción completa

Detalles Bibliográficos
Autores principales:	Höybye, Charlotte, Pfeiffer, Andreas F H, Ferone, Diego, Christiansen, Jens Sandahl, Gilfoyle, David, Christoffersen, Eva Dam, Mortensen, Eva, Leff, Jonathan A, Beckert, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424766/ https://www.ncbi.nlm.nih.gov/pubmed/28196799 http://dx.doi.org/10.1530/EC-17-0007

Ejemplares similares

The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency
por: Sprogøe, Kennett, et al.
Publicado: (2017)

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP
por: Breinholt, Vibeke Miller, et al.
Publicado: (2022)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults
por: Karpf, David B, et al.
Publicado: (2020)

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
por: Maniatis, Aristides K, et al.
Publicado: (2020)

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
por: Thornton, Paul, et al.
Publicado: (2019)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

OP Transcon 2018 Compilation
Publicado: (2019)

PP Transcon 2018 Compilation
Publicado: (2019)

TRANSCON 2022 B: Poster Papers
Publicado: (2023)

TRANSCON 2022 B: Oral Abstracts
Publicado: (2023)

Intratumoral delivery of TransCon(™) TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
por: Zúñiga, Luis Alejandro, et al.
Publicado: (2022)

OR29-5 Phase 3 PaTHway Trial: Participants Treated With TransCon PTH Achieved Independence From Conventional Therapy While Maintaining Normal Serum Calcium
por: Khan, Aliya
Publicado: (2022)

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial
por: Savarirayan, Ravi, et al.
Publicado: (2023)

Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement?
por: Höybye, Charlotte, et al.
Publicado: (2014)

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
por: Rosen, David B, et al.
Publicado: (2022)

38(th) ISBTI Annual Conference, TRANSCON 2013, Surat
Publicado: (2014)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Twenty Years of GH Treatment in Adults with Prader-Willi Syndrome
por: Sjöström, Anna, et al.
Publicado: (2021)

39(th) ISBTI Annual Conference, TRANSCON 2014, Surat Patiala
Publicado: (2015)

40(th) ISBTI Annual Conference, TRANSCON 2015, New Delhi
Publicado: (2016)

THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
por: Savarirayan, Ravi, et al.
Publicado: (2023)

GH Replacement in the Elderly: Is It Worth It?
por: Ricci Bitti, Silvia, et al.
Publicado: (2021)

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations
por: Christiansen, Jens Sandahl, et al.
Publicado: (2016)

Growth hormone (GH)–releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus?
por: Hersch, Elizabeth C, et al.
Publicado: (2008)

A long-acting GH receptor antagonist through fusion to GH binding protein
por: Wilkinson, Ian R., et al.
Publicado: (2016)

Growth Hormone (GH) Hypersecretion and GH Receptor Resistance in Streptozotocin Diabetic Mice in Response to a GH Secretagogue
por: Johansen, Peter B., et al.
Publicado: (2003)

Growth Hormone (GH) and Cardiovascular System
por: Caicedo, Diego, et al.
Publicado: (2018)

Effects of recombinant growth hormone (GH) replacement and psychomotor and cognitive stimulation in the neurodevelopment of GH-deficient (GHD) children with cerebral palsy: a pilot study
por: Devesa, Jesús, et al.
Publicado: (2011)

Reach further
por: Christiansen, Jens Sandahl
Publicado: (2012)

TRANSCON 2020 45(th) Annual Conference ISBTI 27(th) & 28(th) Feb 2021
Publicado: (2021)

Accuracy and Limitations of the Growth Hormone (GH) Releasing Hormone-Arginine Retesting in Young Adults With Childhood-Onset GH Deficiency
por: Patti, Giuseppa, et al.
Publicado: (2019)

Insulin and GH Signaling in Human Skeletal Muscle In Vivo following Exogenous GH Exposure: Impact of an Oral Glucose Load
por: Krusenstjerna-Hafstrøm, Thomas, et al.
Publicado: (2011)

Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency
por: Cohen-Barak, Orit, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gusucp5qb1983solbc6aqg5ua4